AR100768A1 - Método para disminuir la inmunogenicidad de proteínas y péptidos - Google Patents

Método para disminuir la inmunogenicidad de proteínas y péptidos

Info

Publication number
AR100768A1
AR100768A1 ARP150101804A ARP150101804A AR100768A1 AR 100768 A1 AR100768 A1 AR 100768A1 AR P150101804 A ARP150101804 A AR P150101804A AR P150101804 A ARP150101804 A AR P150101804A AR 100768 A1 AR100768 A1 AR 100768A1
Authority
AR
Argentina
Prior art keywords
peptide
physiologically active
vehicle
active protein
immunogenicity
Prior art date
Application number
ARP150101804A
Other languages
English (en)
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR100768A1 publication Critical patent/AR100768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Un procedimiento para disminuir la inmunogenicidad de una proteína o péptido fisiológicamente activos en comparación con aquella de una proteína o péptido fisiológicamente activos a los que no está unido un vehículo, que comprende unir un vehículo al residuo interno, no terminal de la proteína o péptido fisiológicamente activos. Reivindicación 14: Una composición, que comprende un conjugado de una proteína o péptido fisiológicamente activos en el que un vehículo está unido al residuo interno, no terminal de una proteína o péptido fisiológicamente activos, a través de un conector no peptidilo, en el que el conjugado exhibe inmunogenicidad disminuida en comparación con aquella de la proteína o péptido fisiológicamente activos al que el vehículo no está unido. Reivindicación 16: La composición de acuerdo a la reivindicación 14, en el que el conector no peptidilo es un polietilenglicol.
ARP150101804A 2014-06-05 2015-06-05 Método para disminuir la inmunogenicidad de proteínas y péptidos AR100768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140068660A KR20150140177A (ko) 2014-06-05 2014-06-05 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Publications (1)

Publication Number Publication Date
AR100768A1 true AR100768A1 (es) 2016-11-02

Family

ID=54767003

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101804A AR100768A1 (es) 2014-06-05 2015-06-05 Método para disminuir la inmunogenicidad de proteínas y péptidos

Country Status (19)

Country Link
US (2) US20170100488A1 (es)
EP (2) EP4219565A1 (es)
JP (2) JP7125249B2 (es)
KR (4) KR20150140177A (es)
CN (1) CN106661118A (es)
AR (1) AR100768A1 (es)
AU (1) AU2015269039B2 (es)
BR (1) BR112016028227A2 (es)
EA (1) EA035964B1 (es)
HU (1) HU231605B1 (es)
IL (1) IL249131A0 (es)
MX (2) MX387764B (es)
MY (1) MY193519A (es)
NO (1) NO20161980A1 (es)
PH (1) PH12016502430B1 (es)
SG (2) SG10202104313PA (es)
TW (1) TW201625314A (es)
UA (1) UA124183C2 (es)
WO (1) WO2015186988A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
JP7618383B2 (ja) * 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
CN110291103A (zh) * 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
JP2020506932A (ja) * 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
JP7379323B2 (ja) * 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
EP4705331A1 (en) * 2023-05-01 2026-03-11 Neuraly Inc. Glucagon-like peptide-1 receptor agonist variants and methods thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1779859B1 (en) * 1999-12-08 2010-06-09 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants in preventing or treating rejection following transplantation and for induction of apoptosis of activated CD4 or CD8 T-cells
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US8420598B2 (en) * 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
BRPI1013626B8 (pt) * 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
JP2012256007A (ja) 2011-06-10 2012-12-27 Nippon Zeon Co Ltd パターン位相差フィルム用液晶組成物、パターン位相差フィルム及び立体表示装置
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
TWI708782B (zh) 2013-02-26 2020-11-01 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Also Published As

Publication number Publication date
HUP1700024A2 (en) 2017-05-29
SG10202104313PA (en) 2021-06-29
EA201692279A1 (ru) 2017-05-31
EP4219565A1 (en) 2023-08-02
SG11201610098YA (en) 2016-12-29
KR20230023691A (ko) 2023-02-17
WO2015186988A1 (en) 2015-12-10
MX2016015668A (es) 2017-02-27
HU231605B1 (hu) 2025-03-28
IL249131A0 (en) 2017-01-31
BR112016028227A2 (pt) 2017-10-24
TW201625314A (zh) 2016-07-16
US20170100488A1 (en) 2017-04-13
US20220118103A1 (en) 2022-04-21
MY193519A (en) 2022-10-17
KR20210111190A (ko) 2021-09-10
EP3152236A1 (en) 2017-04-12
EA035964B1 (ru) 2020-09-07
PH12016502430A1 (en) 2017-03-06
MX2021006021A (es) 2021-07-06
UA124183C2 (uk) 2021-08-04
CA2950576A1 (en) 2015-12-10
JP2017521381A (ja) 2017-08-03
NO20161980A1 (en) 2016-12-14
MX387764B (es) 2025-03-18
JP2021028329A (ja) 2021-02-25
CN106661118A (zh) 2017-05-10
KR20150140177A (ko) 2015-12-15
NZ726490A (en) 2024-07-26
AU2015269039A1 (en) 2016-12-08
KR20240158214A (ko) 2024-11-04
AU2015269039B2 (en) 2020-12-10
JP7125249B2 (ja) 2022-08-24
PH12016502430B1 (en) 2024-01-05
EP3152236A4 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
WO2018160754A3 (en) Inducible monovalent antigen binding protein
PH12020551716A1 (en) Anti-ror antibody constructs
TW201613958A (en) MIC-1 fusion proteins and uses thereof
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
CO2018000303A2 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
EP4541424A3 (en) Immunomodulatory antibodies
EP3889185A3 (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
MX421186B (es) Constructos de anticuerpos.
CL2016001405A1 (es) A peptide mixture
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
UA118167C2 (uk) Пептид та його застосування
EA201792245A1 (ru) Биоконъюгаты и их применения
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.